Philipp Bürling, MBA
CEO
Philipp Bürling, MBA
Prof. Dr. Dieter Willbold
CSO
Prof. Dr. Dieter Willbold
Prof. Dr. Dieter Willbold is a biochemist, biophysicist and structural biologist. He has headed the Institute of Physical Biology at Heinrich Heine University Düsseldorf since 2004 and was Director of the Institute of Biological Information Processes (IBI-7) at Forschungszentrum Jülich from 2005 to 2025. Prior to this, he studied biochemistry (1985-1991) in Tübingen, Bayreuth and Colorado, obtained his doctorate in Bayreuth in 1994 and habilitated there in 1998 – with a research stay in Tel Aviv – before heading a junior research group in Jena (1998-2001). In 2017, he was the initiator and co-founder of Priavoid and has been driving the further development of the platform as Chief Science Officer since June 2025. He is also the founder of the biomolecular NMR network bio N³MR, a board member of the BMFZ Düsseldorf since 2000 and co-speaker of various graduate schools (BioStruct, iGRASP). He has received several awards for his scientific contributions, including the Research Prize of the University of Bayreuth (1995), the Gerhard Hess Prize of the DFG (2000), the Innovation Prize of the Bioregions and other honors.
Prof. Dr. med. Oliver Peters
CMO
Prof. Dr. med. Oliver Peters
Prof. Oliver Peters studied human medicine and worked at Charité Berlin from 2003 to 2023, where he specialized in geriatric psychiatry and dementia research. From 2008, he took over the position of senior physician at the geriatric psychiatry day clinic and headed the memory consultation and the Center for Dementia Prevention at the ECRC. He qualified as a professor in 2014 and was appointed to a W2 professorship in geriatric psychiatry in 2019. Prof. Peters has been Chief Physician of the Clinic for Psychiatry and Psychotherapy at Klinikum Frankfurt (Oder) since January 2024. He is intensively involved in clinical research, with a focus on biomarker-based preclinical diagnostics of chronic neurodegenerative dementia. Prof. Peters is a board member of the Dementia Competence Network (KND e.V.) and the Hirnliga e.V. and Principal Investigator at the German Center for Neurodegenerative Diseases (DZNE Berlin). He has been part of the management of Priavoid GmbH as Chief Medical Officer since July 2025.
Dr. Antje Willuweit
Director Preclinical Development
Dr. Antje Willuweit
Dr. Antje Willuweit studied Biology at the Technical University of Darmstadt (Germany), received her PhD from the Max-Planck-Institute in Bad Nauheim (Germany) and completed her habilitation at Heinrich Heine University in Düsseldorf (Germany). She gained 9 years of industrial experience in the following Biotech companies: Artemis Pharmaceuticals GmbH, Evotec Neurosciences AG, Evotec AG. In 2011 she joined the Jülich Research Centre at the Institute of Neuroscience and Medicine (INM-4), where she established her own research group. In total, she has got 20 years of experience with animal models in preclinical research, including at least 13 years in the field of preclinical drug testing against Alzheimer´s disease and other neurodegenerative diseases. She co-founded Priavoid in 2017 and is since then Director of Preclinical Research.
Dr. Dagmar Jürgens
Director Clinical Development
Dr. Dagmar Jürgens
Dr. Dagmar Jürgens studied Agricultural Sciences at University of Göttingen (Germany) and subsequently earned her PhD at the University of Gießen. She gained experience at national and international levels since 1990, after founding and leading a small and medium-sized biotech enterprise for more than 15 years. In 2006 she changed her focus to Clinical Research and Drug Development. She furthered her experience in Phase II and III Clinical Trials, whilst working at the German Competent Authority (BfArM) and with international Contract Research Organizations. She has been working at the Jülich Research Center since 2011, first at the Technology Transfer Department, and then at the Institute of Complex Systems (ICS-6), where she is the Project Manager for Preclinical and Clinical Research. She co-founded Priavoid in 2017 and is since then Director of Clinical Development.
Dr. Knut Adermann
Director CMC
Dr. Knut Adermann
Dr. Knut Adermann has more than 20 years experience in peptide therapeutics discovery, translational medicine and clinical development, with a focus on the chemistry, manufacturing and control of novel, peptide active pharmacological ingredients. He holds a PhD in organic chemistry and has co-founded several biotech start-ups, pursuing indications in the fields of antivirals and antibacterials. He was involved in the successful sourcing of seed and round A financing for various start-up companies and has served as managing and scientific director of these ventures. As a consultant in peptide development, he has also supported various preclinical and clinical programs in cardiology, hematology and metabolic diseases. He is an author of more than 90 publications and is a co-inventor of numerous internationally filed patents and patent applications. He co-founded Priavoid in 2017 and is since then Director of CMC.
Dr. Gunther Kauselmann
Director Quality Management and Regulatory Compliance
Dr. Gunther Kauselmann
Dr. Gunther Kauselmann studied Biology at the University of Hamburg and completed his PhD at the Center for Molecular Neuroscience Hamburg (ZMNH). In 1998 he joined the startup company Artemis Pharmaceuticals GmbH in Cologne, which was renamed Taconic Biosciences GmbH after being acquired by Taconic Biosciences Inc. in 2009. At Taconic Dr. Kauselmann held several management positions in scientific operations, quality management and regulatory compliance with increasing responsibility, before being appointed as Vice President of Operations to oversee the production process at the Cologne site. During his professional career he also graduated in Drug Regulatory Affairs and obtained his Master´s Certificate from the University of Bonn. He co-founded Priavoid in 2017 and is since then Director of Quality Management and Regulatory Compliance.